Effectiveness of Monovalent Rotavirus Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan Children. (20th July 2019)

• Record Type: Journal Article
• Authors: Khagayi, Sammy; Omore, Richard; Otieno, Grieven P; Ogwel, Billy; Ochieng, John B; Juma, Jane; Apondi, Evans; Bigogo, Godfrey; Onyango, Clayton; Ngama, Mwanajuma; Njeru, Regina; Owor, Betty E; Mwanga, Mike J; Addo, Yaw; Tabu, Collins; Amwayi, Anyangu; Mwenda, Jason M; Tate, Jacqueline E; Parashar, Umesh D; Breiman, Robert F; Nokes, D James; Verani, Jennifer R
• Is Part Of: Clinical infectious diseases. Volume 70:Number 11(2020)
• Page Start: 2298
• Page End: 2305
• Publication Date: 2019-07-20
• Subjects: rotavirus -- acute gastroenteritis -- vaccine effectiveness -- Kenya; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz664
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Rotavirus remains a leading cause of pediatric diarrheal illness and death worldwide. Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children. Methods: Between July 2014 and December 2017, we conducted surveillance for acute gastroenteritis (AGE) in 3 Kenyan hospitals. From children age-eligible for ≥1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history we compared RV1 coverage among rotavirus positive (cases) vs rotavirus negative (controls) using multivariable logistic regression and calculated effectiveness based on adjusted odds ratio. Results: Among 677 eligible children, 110 (16%) were rotavirus positive. Vaccination data were available for 91 (83%) cases; 51 (56%) had 2 RV1 doses and 33 (36%) 0 doses. Among 567 controls, 418 (74%) had vaccination data; 308 (74%) had 2 doses and 69 (16%) 0 doses. Overall 2-dose effectiveness was 64% (95% confidence interval [CI], 35%–80%); effectiveness was 67% (95% CI, 30%–84%) for children aged <12 months and 72% (95% CI, 10%–91%) for children aged ≥12 months. Significant effectiveness was seen in children with normal weight for age, length/height for age and weight for length/height; however, no protection was found among underweight, stunted, or wasted children. Conclusions: RV1 in the Kenyan immunization program provides significant protection against rotavirus-associated hospitalization which persisted beyond infancy. Malnutrition appears to diminish vaccine effectiveness. Efforts to improve rotavirus uptake and nutritional status are important to maximize vaccine benefit.